CSF Abeta42, tau and phosphorylated tau correlate with medial temporal lobe atrophy

Sanna-Kaisa Herukka1, Corina Pennanen, Hilkka Soininen

  • 1Department of Neurology, University of Kuopio, Kuopio, Finland. sanna-kaisa.herukka@uku.fi

Insights

Cerebrospinal fluid biomarkers and medial temporal lobe atrophy predict Alzheimer's progression in mild cognitive impairment. Lower Abeta42 and higher tau/phospho-tau levels, along with reduced brain volumes, indicate neurodegeneration.

Area of Science:

  • Neurology
  • Biomarkers
  • Neuroimaging

Background:

  • Mild cognitive impairment (MCI) can progress to Alzheimer's disease (AD).
  • Cerebrospinal fluid (CSF) biomarkers and medial temporal lobe (MTL) atrophy are known predictors of this progression.
  • Investigating the interplay between these markers is crucial for early AD detection.

Purpose of the Study:

  • To examine the association between CSF biomarkers and MTL atrophy.
  • To assess the predictive capability of these measures for AD progression in MCI patients.
  • To clarify the temporal relationship between biomarker changes and atrophy.

Main Methods:

  • Studied 21 MCI patients, with 8 progressing to AD.
  • Measured CSF biomarkers (Abeta42, tau, phospho-tau) using ELISA.
  • Assessed MTL structure volumes via magnetic resonance imaging (MRI).

Main Results:

  • Progressive subjects showed lower Abeta42 and higher tau/phospho-tau levels.
  • Progressive subjects exhibited reduced volumes in all MRI measures.
  • Tau and phospho-tau correlated inversely with hippocampal and entorhinal cortex volumes.

Conclusions:

  • Both CSF biomarkers and MTL atrophy appear to reflect neurodegeneration in progressive MCI.
  • The precise order of biomarker changes and atrophy requires further investigation due to study limitations.